150840-28-1

Basic information

• Product Name: 7-{[(3beta)-3-hydroxy-28-oxolup-20(29)-en-28-yl]amino}heptanoic acid
• CAS NO: 150840-28-1
• Molecular Formula: C₃₇H₆₁NO₄
• Molecular Weight: 583.8845
• Mol File: 150840-28-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 704.8°C at 760 mmHg
• Flash Point: 380°C
• Density: 1.061g/cm³
• Vapor Pressure: 5.86E-23mmHg at 25°C
• Refractive Index: 1.527
• CAS DataBase Reference: 7-{[(3beta)-3-hydroxy-28-oxolup-20(29)-en-28-yl]amino}heptanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 7-{[(3beta)-3-hydroxy-28-oxolup-20(29)-en-28-yl]amino}heptanoic acid(150840-28-1)
• EPA Substance Registry System: 7-{[(3beta)-3-hydroxy-28-oxolup-20(29)-en-28-yl]amino}heptanoic acid(150840-28-1)

Safety Data

• Hazardous Substances Data: 150840-28-1(Hazardous Substances Data)

Upstream product

• 10376-50-8 3-O-acetylbetulinic acid 
• 1169880-18-5 C₄₆H₆₉NO₅ 
• 59868-82-5 3-O-acetylbetulinic acid chloride 
• 17994-94-4 methyl 7-aminoheptanoate hydrochloride 

Relevant articles and documents

New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1

Bevirimat (1, BVM) is an anti-HIV agent that blocks HIV-1 replication by interfering with HIV-1 Gag-SP1 processing at a late stage of viral maturation. However, clinical trials of 1 have revealed a high baseline drug resistance that is attributed to naturally occurring polymorphisms in HIV-1 Gag. To overcome the drug resistance, 28 new derivatives of 1 were synthesized and tested against compound 1-resistant (BVM-R) HIV-1 variants. Among them, compound 6 exhibited much improved activity against several HIV-1 strains carrying BVM-R polymorphisms. Compound 6 was at least 20-fold more potent than 1 against the replication of NL4-3/V370A, which carries the most prevalent clinical BVM-R polymorphism in HIV-1 Gag-SP1. Thus, compound 6 merits further development as a potential anti-AIDS clinical trial candidate.

Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors

Wepreviously reported that [[N-[3β-hydroxyllup-20(29)-en-28-oyl]-7- aminoheptyl]carbamoyl]methane (A43D, 4) was a potent HIV-1 entry inhibitor. However, 4 was inactive against HIV-2 virus, suggesting the structural requirements for targeting these two ret

Lupane derivatives, their preparation and the pharmaceutical compositions which contain them

The present invention relates to new lupane dervivatives of the general formula: STR1 to their salts, to their preparation and to the pharmaceutical compositions which contain them.